Peritoneal mesothelioma should be how is it treated?

(A) treatment
The effect of radiotherapy and chemotherapy in general are dissatisfied with some reports in recent years, treatment with adriamycin, 50% of cases extended the survival time but there are also reports that some people advocate the use of ineffective immune therapy requires further observation is generally 1 to 2 years after diagnosis the death date So far peritoneal mesothelioma is still a lack of standardized treatment for the vast majority of scholars, advocates, including radiotherapy and chemotherapy after surgical removal of a comprehensive treatment of
1. Surgical treatment for stage of disease are cases of stage Ⅰ Stage Ⅱ surgical treatment should still be the preferred or to gain, including surgical resection Palliative resection of the tumor lesions smaller than its predecessor should complete resection of tumor and involved organs; if more extensive lesions should seek to remove the main tumor (palliative resection) on the disease has caused widespread and serious intestinal surgery can not be considered palliative resection surgery to relieve the patient's clinical symptoms and biological behavior of benign low-grade malignant peritoneal mesothelioma Surgical resection can be very good if re-resection recurrence Zhu Wei-qi and other reports one cases of malignant peritoneal mesothelioma 20 years because of repeated recurrence of surgical resection has implemented five times reported in the literature surgical resection alone a set of best cases (7 cases ), the median survival period of 147.2 months and therefore some cases of peritoneal mesothelioma, surgery is still regarded as effective treatment
2. Radiotherapy, including external beam radiotherapy and (or) irradiation can choose 60Co or 186 kV X-ray radiation source, as applicable to incomplete resection or unresectable disease cases Keyi range determines the full abdominal irradiation or local irradiation is generally believed that peritoneal pleural mesothelioma, mesothelioma radiation therapy as effective as a good which may be related pleural mesothelioma, a larger dose of radiation used in the Shanghai Medical University Cancer Hospital data show that the whole abdominal irradiation dose per 6 ~ 7 weeks 2400cGy patients with local recurrence rate can be fell to 11.4% three-year survival rate was 66.7% shows the effect of radiotherapy on peritoneal mesothelioma is in the affirmative
3. Chemotherapy on reports of chemotherapy in the treatment of peritoneal mesothelioma, peritoneal mesothelioma, many now considered moderately sensitive to chemotherapy is commonly used drugs: doxorubicin (ADM) and cisplatin (DDP) vincristine (VCR) ring phosphorus amide (CTX) bleomycin (BLM), as well as domestic anti-cancer drugs such as mixing elements of which the fragrant milk over the efficacy of doxorubicin chemotherapy is most certainly is divided into systemic chemotherapy and intraperitoneal chemotherapy
(1) systemic chemotherapy: systemic anti-cancer drugs given to the distribution of drugs after the intra-abdominal foreign data show that less whether single agent or combination therapy with chemotherapy effective only 11% ~ 14% of combined chemotherapy, including: DDP + ADM; DDP + CTX + VCR; CTX + VCR + BLM, etc. However, many scholars have pointed out and would not improve efficacy of combination chemotherapy
(2) Intraperitoneal chemotherapy: In recent years that the intraperitoneal injection drug use can increase local drug concentration to reduce systemic adverse reactions of doxorubicin intraperitoneal chemotherapy can not only eliminate residual tumor tissue after surgery to reduce recurrence and also enable some patients to lose the opportunity to tumor surgery reduce the disease has been effectively controlled with ascites to reduce intra-abdominal and intravenous dose once a dosage similar to or slightly higher than the latter to repeat the condition of patients after 1 week of continuous injection of Ito and so on for several weeks to one cases of surgical resection for patients unable to intraperitoneal injection of DDP and jointly with the of uracil and tegafur 223 days after the patients had no abdominal mass ascites completely disappeared but in the first 8 months after the recurrence of pelvic masses re-DDP and camptothecin effect is given to poor Ma and so on are continuous hyperthermic peritoneal perfusion with heat (continuous hyperthermic peritoneal perfusionCHPP) local injection of DDP combined treatment of primary peritoneal mesothelioma course of treatment, no significant local adverse reactions CHPP Patients are able to withstand 10 months of follow-up of non-one cases of death due to CHPP treatment
33P intraperitoneal injection in the treatment of peritoneal mesothelioma, there is a certain effect has been reported by injection of 33P intracavitary radiotherapy and cyclophosphamide in the treatment of malignant peritoneal mesothelioma patients survive up to 17 years are also useful in the treatment of intraperitoneal injection of radioactive colloid reports
4. Biological response modifier biological response modifier (biological nesponse modifierBRM) is to apply some of the body's own cellular and molecular responses to stimulate the body's internal and external environment and thus to participate to maintain the stability of the body environment, through the mobilization of the body BRM inherent capacity to resist and eliminate cancer as Today a new model for tumor therapy
Cytokine interleukin (IL) interferon (IFN) tumor necrosis factor (TNF), etc. In addition to directly kill the tumor cells outside the body and can be activated anti-cancer effects against cancer cells or secreted factors or the maintenance of immune effector cell proliferation and differentiation of function as adjuvant treatment of primary peritoneal mesothelioma
Adoptive transfer of immune cells collected in the separation of lymphocytes in malignant ascites, and induced in vitro expansion of activity with the anti-Lymphokine-activated killer (LAK) will be injected into the body of the tumor cells, anti-IL-2 can be given at the same time improve the efficacy of
(B) the prognosis
Treatment of malignant peritoneal mesothelioma, if not the majority in the survival after diagnosis is only one more than a year died from cachexia or small-bowel obstruction cytoreductive surgery and complete intra-abdominal chemotherapy to improve treatment methods such as direct impact on the prognosis of patients has been reported cytoreductive surgery and intraperitoneal chemotherapy Multi-method combination therapy to peritoneal mesothelioma, the average survival time of up to 50 to 60 months among women in relatively good prognosis of the biological behavior of tumor itself also has important prognostic significance of a group of 4710 cases reported in the literature the analysis of data indicate that epithelial mixed-type and fiber type in the median survival of 11 months, respectively 10 months and 5 months